COPD exacerbation

Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism

J A Wedzicha, J R Hurst

Pulmonary embolism is not a common feature in patients with chronic obstructive pulmonary disease with uncomplicated exacerbations

Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of acute deterioration in respiratory symptoms that are accompanied by physiological changes and associated with increases in airway and systemic inflammation. These episodes are responsible for considerable morbidity and mortality, especially in patients with more severe COPD. There is consequently much interest in understanding the underlying pathophysiology of exacerbations and determining their triggers, so that appropriate interventions can be designed to prevent these events, reduce their severity and thus improve health status.

We now recognise that respiratory infections are important triggers of exacerbation. Respiratory viral infections, especially with human rhinovirus (the cause of the common cold), influenza and respiratory syncytial virus may be isolated from up to 60% of exacerbations.  

Exacerbations where a virus is isolated have increased airway and systemic inflammatory changes. The role of bacteria at exacerbation has been more difficult to determine as airway bacteria are also found in stable patients with COPD, especially those with more severe COPD. However, we now know that bacterial strain change may play a part in triggering exacerbation. Airway bacteria may be present in up to 70% of exacerbations, and their isolation is associated with increased airway inflammatory changes.  

Viruses and bacteria may also be co-isolated from the same exacerbation, and recent studies have suggested that the presence of both pathogens may have a synergistic effect on the degree of airway inflammation, especially when exacerbations are severe. Thus, airway infection can be implicated as a trigger in most COPD exacerbations, even taking into account difficulties in sampling these patients that can lead to underestimating the significance of airway infection.  

There is also interest in other causes of COPD exacerbation. Air pollution has been associated with an increase in hospital admissions in patients with COPD, although these effects are relatively small. As COPD exacerbations are closely linked to respiratory infections, the hypothesis has been put forward that pollutants can increase susceptibility to viral infection. One study has suggested that with higher personal nitrogen dioxide exposure, there is a greater risk of an asthmatic exacerbation after respiratory virus infection. Similar mechanisms might be operating in patients with COPD and further studies investigating the associations between pollution and infection are required.

Exacerbations therefore result from further insult to the COPD airway, but a number of conditions may mimic exacerbation by causing worsening dyspnoea in patients with underlying COPD. One such condition is pulmonary embolism, a disorder of the vasculature rather than the airway. Although pulmonary embolism is not thought to predispose to exacerbation, there have been a number of reports suggesting that the prevalence of deep venous thrombosis and pulmonary
embolism is increased in patients with COPD exacerbation (although earlier results were based on small studies in selected hospitalised patients11–13). The hypothesis that COPD exacerbations may trigger pulmonary embolic events is plausible as acute infections are known to predispose to deep venous thrombosis and pulmonary embolism.24 Furthermore, patients with COPD are often elderly, may be immobile, and often have systemic inflammation and co-morbid conditions, all of which increase susceptibility to venous thromboembolism. There may also be diagnostic difficulties as both COPD exacerbations and pulmonary embolism may present solely with dyspnoea. A recent study by Tillie-Leblond et al11 reported a 25% prevalence of pulmonary embolism in patients with COPD hospitalised for severe exacerbations “of unknown origin”. An unusual feature of this study was that the authors excluded all patients in whom a potential infective cause for exacerbation was identified: they excluded exacerbations associated with increased sputum volume or sputum purulence, or a history of colds and sore throats, which indicates viral infection. Thus, the patients recruited into this study were highly selected and not representative of most exacerbations presenting to primary or secondary care that are usually accompanied by some manifestation of airway infection. In this study, exacerbations were defined as an acute deterioration requiring hospitalisation, and it is not clear whether patients just presented with worsening symptoms of dyspnoea or may have developed other conditions such as heart failure that could increase the risk of pulmonary embolism.

In this issue of Thorax, Rutschmann et al11 describe a further interesting study investigating the prevalence of pulmonary embolism at COPD exacerbations. (see page 121) In contrast with the study by Tillie-Leblond, Rutschmann et al included consecutive patients admitted to emergency departments with COPD exacerbations and investigated all the patients for pulmonary embolism, regardless of clinical suspicion. Investigation involved a standardised algorithm based on D-dimer testing, lower limb venous ultrasonography and multidetector helical computerised tomography scan. The data showed that the prevalence of pulmonary embolism was 6.2% in patients with COPD with clinical suspicion of pulmonary embolism, and only 1.3% where there was no clinical suspicion of pulmonary embolism. The authors conclude that as the prevalence of pulmonary embolism is so low, systematic investigation in patients presenting with COPD exacerbations is not required.

So is this the final conclusion: that pulmonary embolism is not an issue in patients with COPD with uncomplicated exacerbations? The results of this study are consistent with the clinical observation that most moderate to severe exacerbations in patients with COPD last between 7 and 10 days, respond well to therapy, and recover to their baseline symptoms and lung function. Some patients with COPD are prone to frequent exacerbations; they may be susceptible to respiratory viral infections and are these patients more prone to develop PE? Perhaps, however, these patients are more prone to developing pulmonary embolism. Furthermore, we also recognise that in some patients, an index COPD exacerbation may be followed closely in time by another “recurrent” exacerbation, and this is consistent with the observation that patients admitted to hospital with exacerbations are subsequently at an increased risk of readmission.24 It is thus possible that in addition to airway infection, venous thromboembolism may play a part in exacerbation recurrence.

Airway infection is the most important trigger of COPD exacerbations, and strategies to reduce airway viruses and bacteria should be the most effective interventions to prevent or reduce these events. The paper by Rutschmann et al suggests that pulmonary embolism is not a common feature of the uncomplicated exacerbation at presentation. However, some exacerbations can have prolonged recovery periods, complicated by respiratory failure and co-morbidity, when the risk of pulmonary embolism may become greater. It is these exacerbations that have particular health economic implications and require our future efforts.


Authors’ affiliations
J A Wedzicha, J R Hurst, Academic Unit of Respiratory Medicine, Royal Free and University College Medical School, University College London, Hampstead, UK

J A Wedzicha, J R Hurst, Academic Unit of Respiratory Medicine, Royal Free and University College Medical School, University College London, Hampstead, UK

Correspondence to: Professor J A Wedzicha, Academic Unit of Respiratory Medicine, Royal Free and University College Medical School, University College London, Rowland Hill Street, Hampstead NW3 2PF, UK; i.a.wedzicha@mdschd.ac.uk

Competing interests: None declared.

REFERENCES
Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism

J A Wedzicha and J R Hurst

Thorax 2007 62: 103-104
doi: 10.1136/thx.2006.073098

Updated information and services can be found at:
http://thorax.bmj.com/content/62/2/103

These include:

References
This article cites 22 articles, 10 of which you can access for free at:
http://thorax.bmj.com/content/62/2/103#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/62/4/371.3.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections

- Pulmonary embolism (140)
-Venous thromboembolism (157)
-Inflammation (1020)
-TB and other respiratory infections (1273)
-Epidemiologic studies (1829)
-Air pollution (110)
-Asthma (1782)
-Environmental issues (253)
-Influenza (106)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Pulmonary hypertension in Hodgkin’s disease

We wish to share our experience in an unusual case presentation of pulmonary hypertension. A 48-year-old Caucasian female with a history of hypothyroidism and smoking presented with progressive dyspnoea on exertion for 3 years, markedly worse during the past 6 months. She also had arthralgias, Raynaud’s phenomenon, night sweats and a 25-pound weight loss over 6 months. Chest computed tomography scan showed diffuse mediastinal lymphadenopathy. Lymph node biopsy showed non-necrotising epithelioid granulomas compatible with sarcoidosis. Symptoms worsened despite treatment with prednisone.

Pulmonary function tests showed mild restrictive disease, reduced diffusion capacity and desaturation during a 6-min walk. Echocardiogram showed a severely dilated and hypokinetic right ventricle. Right heart catheterisation showed pulmonary artery pressure 79/38 mm Hg (mean 46 mm Hg), cardiac output 6.7 l/min and cardiac index 3.7 l/min/m². There was no significant response to inhaled nitric oxide at 20 ppm.

A retrospective review of her pathology showed a reaction pattern consistent with sarcoidosis, small foci of paracortical infiltration by large mononuclear and binucleated haematopoietic elements, and a concordant background of tissue eosinophilia. Immunohistostaining was consistent with mixed cellularity Hodgkin’s lymphoma (fig 1).

She was initiated on epoprostenol by continuous infusion. Owing to her pulmonary and cardiac disease, she received six cycles of chlorambucil, vinblastine, procarbazine and prednisone. She achieved a complete response and remains in remission 20 months after chemotherapy. She continues on epoprostenol therapy with improved exercise tolerance. Repeat right heart catheterisation showed pulmonary artery pressure 48/21 (mean 30 mm Hg), cardiac output 7.8 l/min and cardiac index 4.6 l/min/m². Attempts to wean epoprostenol were unsuccessful.

Sarcoïd-like reactions are defined as areas of non-caseating granulomas seen on biopsy in patients without symptoms of systemic sarcoidosis. Radiographically, patients with intractable sarcoïd-like reactions may present with hilar or mediastinal adenopathy, ground-glass infiltrates or a perivascular nodularity mimicking sarcoidosis. Among the various conditions associated with a sarcoïd-like diathesis are infections, hypersensitivity reactions, and solid or haematological malignancies. In malignancy, this pathology can be seen at the primary tumour site, particularly in T cell lymphoma and Hodgkin’s disease, in lymph nodes draining the region, or in distant organs such as the spleen, liver or bone marrow. Up to 4.4% of patients with carcinoma, 7.3% of patients with non-Hodgkin’s lymphoma and 13.8% of patients with Hodgkin’s disease will feature sarcoïd-like reactions.

Pulmonary arterial hypertension (PAH) develops in up to 28% of patients with sarcoidosis. The aetiology of PAH in sarcoidosis is generally presumed to be secondary to parenchymal fibrosis and hypoxaemia. However, PAH may develop in patients without extensive parenchymal destruction secondary to perivascular or intravascular granulomatous inflammation, granulomatous angiitis, extrinsic compression of the main or peripheral pulmonary arteries by mediastinal lymph nodes or fibrosis with resultant pulmonary stenosis.

The response of PAH secondary to sarcoïdosis in the treatment for sarcoidosis is uncertain; in a case series, the haemodynamic response to steroid therapy was found to be lagging behind the radiographic and pulmonary function test improvement, and was not universally seen. In a small study, patients with severe PAH secondary to sarcoïdosis were found responsive to vasodilator therapy. PAH in association with sarcoïd-like reactions is not described, and management is unproven.

No cases of PAH secondary to a sarcoïd-like reaction or Hodgkin’s disease have been reported previously. This case underscores the association of lymphoma and sarcoïd-like reactions, and the possibility that PAH in these patients may be underappreciated. This case also emphasises the importance of a systematic evaluation for lymphoproliferative disease in patients with lymphadenopathy presumed to be sarcoidosis.

Matthew Exline, Cynthia Magro, Thomas Lin, Namita Sood
Department of Medicine, Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
Correspondence to: N Sood, Department of Medicine, Department of Pathology, The Ohio State University, Columbus, OH, USA; namita.sood@osumc.edu
doi: 10.1136/thx.2006.070029

Competing interests: None declared.

References

CORRECTIONS

doi: 10.1136/thx.2006.045591corr1

In the paper by Rudd et al (Thorax 2007;62:62–66) from the January issue, the abbreviation TLCO was incorrectly expanded to “reduced carbon monoxide transfer factor”, when in fact it should have been “carbon monoxide transfer factor”. This occurs in the penultimate sentence of the results section of the abstract, the abbreviations list and the legend of figure 1.